期刊文献+

盐酸普拉克索的合成优化 被引量:1

Optimization on synthesis of pramipexole dihydrochloride
原文传递
导出
摘要 目的改进盐酸普拉克索的合成工艺。方法以1,4-环己二酮单乙二醇缩酮为原料,采用“一锅法”对重要中间体2-氨基-6-羟基4,5,6,7-四氢苯并噻唑的合成进行改进,该中间体经进一步叠氮化、还原、拆分、烷基化及成盐反应得到目标化合物盐酸普拉克索。结果与结论合成过程中所有中间体及最终产物的结构均经1H-NMR、13C-NMR确证,总收率为17.4%(以1,4-环己二酮单乙二醇缩酮计),纯度大于99.0%。改进后的工艺为盐酸普拉克索的后续生产和应用研究提供了实验基础。 A"one-pot"method was used to optimize on the synthesis of 2-amino-6-hydroxyM,5,6,7-tetrahydrobenzothiazole(2)with 1,4-cyclohexanedione monoethyleneacetal(1)as the raw material.Compound 2 was a key intermediate in the preparation of pramipexole dihydrochloride.The method has the advantage of simple operation without separation and purification.Pramipexole dihydrochloride was obtained by optimizing the reaction conditions of the azidation,reduction,resolution,alkylation and salt formation with compound 2 as starting material,with the yield of 17.4%.All the intermediates and final products were confirmed by 1H-NMR and 13C-NMR.The results will provide a solid experimental basis for the future production and application of pramipexole dihydrochloride.
作者 陈昊天 孙兰天 辛红兴 闫红 CHEN Hao-tian;SUN Lan-tian;XIN Hong-xing;YAN Hong(College of Life Science and Bioengineering,Beijing University of Technology,Beijing 100124,China;Jumpcan Pharmaceutical Co.,Ltd.,Taizhou 225441,China)
出处 《中国药物化学杂志》 CAS CSCD 北大核心 2019年第2期118-121,共4页 Chinese Journal of Medicinal Chemistry
关键词 普拉克索 抗帕金森症 合成工艺优化 一锅法 pramipexole anti-Parkinsons drugs synthesis process optimization one-pot
  • 相关文献

参考文献7

二级参考文献63

  • 1凌青,李欣,沈竞康.仲胺的合成方法新进展[J].合成化学,2007,15(3):247-253. 被引量:16
  • 2KOLLER WC. Levodopa in the treatment of PD [ J]. Neurology, 2000,55(11 Suppl 4) :S2 - S7.
  • 3COLOSIMO C,MERELLO M,HUGHES AJ,et al. The motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease:implications or the pathogenesis of the on-off phenomenon [ J ]. J Neurol Neurosurg Psychiatry, 1996,60(6) :634 -637.
  • 4BROTHIE JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease [J]. Ann Neurol,2000, 47 (4 Suppl 1) :S105 - S114.
  • 5SYEIGER MJ,STOCCHI F,CARTA A,et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon “off” periods in Parkinson's disease [J]. Clin Neuropharmacol, 1991, 14(3) :241 -244.
  • 6LLEDó A. Dopamine agonists: the treatment for Parkinson's disease in the XXI century? [ J]. Parkinsonism Relat Dis,2001,7 (1) :51 -58.
  • 7THOMAS HJ. An explosion of new drugs for Parkinson's disease [ J ]. Parkinsonism Relat Dis, 1997,3 ( 2 ) :65 - 66.
  • 8METMAN LV, GILLESPIE M, FARMER C, et al. Continuous transdermal dopa-minergic stimulation in advanced Parkinson's disease [ J ]. Clin Neuropharmacol, 2001,24 ( 3 ) : 163 - 169.
  • 9STEPHENSON DT, MEGLASSON MD, CONNELL MA,et al. The effects of a selective D2 receptor agonist on behavioral and pathologic outcome in MPTP-treated squirrel monkeys [J]. J Pharmacol Exp Ther,2005,314 ( 3 ) : 1257 - 1266.
  • 10TINTNER R, MANIAN P, GAUTHIER P, et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease [ J ]. Arch Neurol, 2005,62 ( 8 ) : 1290 - 1295.

共引文献16

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部